A new trading day began on Friday, with Lyra Therapeutics Inc (NASDAQ: LYRA) stock price up 8.55% from the previous day of trading, before settling in for the closing price of $0.11. LYRA’s price has ranged from $0.10 to $5.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 78.20% over the last five years. Meanwhile, its annual earnings per share averaged 42.42%. With a float of $54.86 million, this company’s outstanding shares have now reached $65.52 million.
The firm has a total of 30 workers. Let’s measure their productivity. In terms of profitability, gross margin is -773.53%, operating margin of -6280.83%, and the pretax margin is -6088.4%.
Lyra Therapeutics Inc (LYRA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lyra Therapeutics Inc is 16.73%, while institutional ownership is 37.88%.
Lyra Therapeutics Inc (LYRA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.95% during the next five years compared to -2.22% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Here are Lyra Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Analysing the last 5-days average volume posted by the [Lyra Therapeutics Inc, LYRA], we can find that recorded value of 2.18 million was better than the volume posted last year of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 15.99%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 10.40%, which indicates a significant decrease from 24.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.71% in the past 14 days, which was lower than the 90.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1782, while its 200-day Moving Average is $0.2334. Now, the first resistance to watch is $0.1279. This is followed by the second major resistance level at $0.1352. The third major resistance level sits at $0.1479. If the price goes on to break the first support level at $0.1079, it is likely to go to the next support level at $0.0952. Should the price break the second support level, the third support level stands at $0.0879.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
With a market capitalization of 7.95 million, the company has a total of 65,880K Shares Outstanding. Currently, annual sales are 1,530 K while annual income is -93,440 K. The company’s previous quarter sales were 210 K while its latest quarter income was -10,980 K.
